MedPath

Dose of oxytocin needed during cesarean in patients with pregnancy of less than 37 weeks

Phase 4
Recruiting
Conditions
Encounter for cesarean delivery without indication,
Registration Number
CTRI/2023/05/053088
Lead Sponsor
University College of Medical Sciences and GTB Hospital
Brief Summary

**Objective:**To evaluate and compare during cesarean delivery in patients with *preterm and term* pregnancy, the minimum effective dose (defined as ED90 i.e., dose expected to be adequate in 90% of target population) of prophylactic oxytocin infusion for achieving and maintaining adequate uterine tone.

**Methods:**This will be a dual-arm, dose finding study, based on biased coin sequential allocation design. The patient, anesthesiologist conducting the case, and obstetrician will be blinded to the dose of oxytocin. All women aged >18 years, and posted for cesarean delivery under spinal block will be evaluated for inclusion, either into the term (completed 37 weeks) or preterm (<37 weeks) cohort. Matching will be done in the preterm and term cohorts for categories of confounding variables known to affect association of oxytocin dose and uterine contraction.

***Oxytocin administration:***Oxytocin infusion will be initiated on clamping of the umbilical cord. The dose of the infusion will be 13 IU/h for the first patient in both cohorts. The designated hourly oxytocin dose will be added to normal saline in a 50 mL syringe, and infused via a syringe infusion pump at 50 mL/h. The dose in subsequent cases, for either cohort, will be determined by the response to oxytocin in previous patient of the particular cohort, based on biased sequential allocation method. The primary outcome measure is the adequacy of intraoperative uterine tone at 4 minutes and continued till the end of surgery, assessed by using 1 finger palpation method. When uterine tone is satisfactory, infusion of oxytocin will be continued till the end of surgery at the same rate. In case of an unsatisfactory tone, the infusion will be doubled and uterine massage initiated, followed by additional uterotonic is still required.

***Myometrial oxytocin receptor quantification:***Full thickness myometrial biopsy will be taken from the upper edge of the uterine transverse incision made for cesarean delivery. Routinely formalin fixed paraffin embedded myometrial tissue will then be used for immunohistochemistry using commercially available antibodies to evaluate myometrial oxytocin receptor density (using manufacturers’ instructions) in 10 out of 30 patients from each cohort.

***Other Observations:***These will include additional indications of efficacy of oxytocin, associated side effects and patients characteristics.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Female
Target Recruitment
60
Inclusion Criteria

Posted for cesarean delivery under spinal block; either into the term or preterm cohort (defined as gestational age of completed 37 weeks (i.e., ≥259 days) or <37 weeks respectively.

Exclusion Criteria

Laboring with preoperative oxytocin use, or magnesium sulfate therapy, coagulopathy, history of previous uterine atony or postpartum hemorrhage or bleeding disorder or heart disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Intraoperative uterine toneFrom 4 minutes of oxytocin initiation till end of surgery
Secondary Outcome Measures
NameTimeMethod
Need of additional uterotonic as per obstetrician, for inadequate uterine toneAt ANY time during surgery (after initiating oxytocin to end of surgery)

Trial Locations

Locations (1)

University College of Medical Science and GTB Hospital

🇮🇳

East, DELHI, India

University College of Medical Science and GTB Hospital
🇮🇳East, DELHI, India
Dr Srishty Singla
Principal investigator
9953489108
srishty.singla11@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.